Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3234 |
Name | central nervous system lymphoma |
Definition | A hematologic cancer that has_material_basis_in lymphoma located_in central nervous system. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3233 |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer central nervous system lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Rituximab | central nervous system lymphoma | not applicable | detail... |
Unknown unknown | Ibrutinib | central nervous system lymphoma | not applicable | detail... |
MYD88 L265P | Ibrutinib | central nervous system lymphoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00267865 | Phase II | Rituximab Methotrexate Leucovorin | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | Completed | USA | 0 |
NCT00293475 | Phase Ib/II | Filgrastim Pegfilgrastim Leucovorin Carboplatin + Methotrexate + Rituximab | Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD); Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL | Recruiting | USA | 0 |
NCT00621036 | Phase II | Methotrexate Thiotepa Sargramostim | Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma | Withdrawn | USA | 0 |
NCT02203526 | Phase I | Dexamethasone + Etoposide + Ibrutinib + Pegylated liposomal-doxorubicin + Temozolomide Cytarabine Rituximab | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma | Recruiting | USA | 0 |
NCT02301364 | Phase II | Buparlisib | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | Completed | USA | 0 |
NCT02315326 | Phase Ib/II | Ibrutinib | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | Active, not recruiting | USA | 0 |
NCT02669511 | Phase II | PQR309 | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | Completed | 0 | |
NCT02857426 | Phase II | Nivolumab | A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647) | Active, not recruiting | USA | CAN | 11 |
NCT03220646 | Phase II | Abemaciclib | The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors. | Recruiting | USA | 0 |
NCT03558750 | Phase Ib/II | Lenalidomide + Nivolumab + Rituximab | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | Terminated | USA | 0 |
NCT03581942 | Phase Ib/II | Copanlisib + Ibrutinib | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | Recruiting | USA | 0 |
NCT03684980 | Phase I | Glucarpidase + Leucovorin + Methotrexate + Rituximab | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A | Recruiting | USA | 0 |
NCT03703167 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | Recruiting | USA | 0 |
NCT03770416 | Phase II | Ibrutinib + Nivolumab | Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | Recruiting | USA | 0 |
NCT03964090 | Phase II | Cytarabine + Dexamethasone + Etoposide + Isavuconazole + Pegylated liposomal-doxorubicin + Rituximab + Temozolomide Cytarabine + Dexamethasone + Etoposide + Ibrutinib + Isavuconazole + Pegylated liposomal-doxorubicin + Rituximab + Temozolomide | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | Recruiting | USA | 0 |
NCT04134117 | Phase I | Tisagenlecleucel | Tisagenlecleucel In Primary CNS Lymphoma | Recruiting | USA | 0 |
NCT04401774 | Phase II | Nivolumab | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | Recruiting | USA | 0 |
NCT04421560 | Phase Ib/II | Ibrutinib + Pembrolizumab + Rituximab | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | Recruiting | USA | 0 |
NCT04462328 | Phase I | Acalabrutinib + Durvalumab | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | Not yet recruiting | USA | 0 |
NCT04548648 | Phase II | Acalabrutinib Isavuconazole | LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | Not yet recruiting | USA | 0 |
NCT04608487 | Phase I | Cyclophosphamide + Fludarabine KTE-C19 | Axi-cel in CNS Lymphoma | Recruiting | USA | 0 |
NCT04609046 | Phase I | Lenalidomide + Nivolumab Lenalidomide + Methotrexate + Nivolumab + Rituximab | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | Recruiting | USA | 0 |